Managers / Q1 2021 · view latest →
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
CIK 0001047859 · 500 CRESCENT COURT, SUITE 260, DALLAS, TX, 75201 · 2148713700
Summary
Paragon Associates & Paragon Associates II Joint Venture reported $66M in U.S.-listed holdings across 11 positions for Q1 2021.
Its largest position, NEM, represents 18.4% of the portfolio.
Compared with Q4 2020, the fund opened 2 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 94.0% · $62M
- ETP · 6.0% · $4M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CICIGNA CORP NEW | NEW | +20.0K | 20.0K | +$5M | $5M |
| EEFTEURONET WORLDWIDE INC | NEW | +7.5K | 7.5K | +$1M | $1M |
| VERSO CORP | ADDED | +202.7K | 350.0K | +$3M | $5M |
| WFCWELLS FARGO CO NEW | SOLD OUT | −25.0K | 0 | −$755,000 | $0 |
| REATA PHARMACEUTICALS INC | TRIMMED | −40.0K | 100.0K | −$7M | $10M |
| BNYBANK NEW YORK MELLON CORP | TRIMMED | −25.0K | 75.0K | −$691,000 | $4M |
| NEMNEWMONT CORP | TRIMMED | −50.0K | 200.0K | −$3M | $12M |
| IRIXIRIDEX CORP | TRIMMED | −130.0K | 1.19M | +$5M | $8M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | NEMNEWMONT CORPhistory → | COM | 18.37% | $12M | 200.0K |
| 2 | NVGSNAVIGATOR HOLDINGS LTDhistory → | SHS | 17.09% | $11M | 1.26M |
| 3 | REATA PHARMACEUTICALS INC | CL A | 15.20% | $10M | 100.0K |
| 4 | IRIXIRIDEX CORPhistory → | COM | 12.24% | $8M | 1.19M |
| 5 | EPSNEPSILON ENERGY LTDhistory → | COM | 8.23% | $5M | 1.38M |
| 6 | VERSO CORP | CL A | 7.78% | $5M | 350.0K |
| 7 | CICIGNA CORP NEWhistory → | COM | 7.37% | $5M | 20.0K |
| 8 | SPYSPDR S&P 500 ETF TRhistory → | TR UNIT | 6.04% | $4M | 10.0K |
| 9 | BNYBANK NEW YORK MELLON CORPhistory → | COM | 5.42% | $4M | 75.0K |
| 10 | EEFTEURONET WORLDWIDE INChistory → | COM | 1.58% | $1M | 7.5K |
| 11 | ATNIATN INTL INC | COM | 0.67% | $442,000 | 9.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $74M | 14 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $48M | 12 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $56M | 12 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $63M | 15 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $43M | 13 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $43M | 12 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $56M | 16 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $41M | 11 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $56M | 16 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $44M | 15 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $31M | 10 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $49M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $48M | 11 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $54M | 17 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $50M | 12 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $51M | 11 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $54M | 7 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $63M | 10 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $88M | 17 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $75M | 16 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $66M | 11 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $65M | 10 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $74M | 8 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $91M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $93M | 13 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $178M | 19 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $130M | 21 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $130M | 25 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $106M | 30 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.